RA0163

antibody from Oursmab

Targeting: CCN2 CTGF, IGFBP8

Western blot (Supportive data in Antibodypedia)

ELISA (Supportive data in Antibodypedia)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0163

Provider

Oursmab

Product name

Pamrevlumab (Biosimilar Reference Antibody) (CTGF)

Antibody type

Monoclonal

Description

Pamrevlumab (also known as FG-3019) is a fully human monoclonal antibody that targets connective tissue growth factor (CTGF, also known as CCN2), a matricellular protein involved in tissue remodeling, fibrosis, and tumor progression. By binding to CTGF, pamrevlumab inhibits its interaction with extracellular matrix components and cell-surface receptors (e.g., integrins), thereby disrupting CTGF-mediated signaling pathways that drive fibrosis, inflammation, and cancer-associated stromal desmoplasia. It has been investigated as an anti-fibrotic and anti-tumor agent for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic ductal adenocarcinoma (PDAC), and Duchenne muscular dystrophy (DMD).

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Pamrevlumab (Biosimilar Reference Antibody) (CTGF)-RA0163-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.

ELISA

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

ELISA plate pre-coated Antigen protein, can bind Pamrevlumab (Biosimilar Reference Antibody) (CTGF)-RA0163 in a linear range of 0.18¨C15 ng/mL.